17beta-estradiol and restenosis: a novel vaso-protective role for estrogen?
Restenosis is the major limitation of percutaneous transluminal coronary angioplasty. Several therapies to prevent restenosis, pharmacological and non-pharmacological, have shown favorable results in experiments, and a few in clinical trials. Evidence is accumulating that 17beta-estradiol, the predominant circulating form of estrogen in premenopausal women, inhibits neointimal formation following arterial injury. Evidence demonstrating the ability of estrogen to suppress neointimal formation and underlying mechanisms are reviewed.
Chandrasekar
Baskaran
B
Vijaya Heart Foundation, Chennai, India. ani_chandra1@yahoo.com
D000818:Animals; D023903:Coronary Restenosis / Q000517:prevention & control*; D004195:Disease Models, Animal; D004958:Estradiol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans
D004958:Estradiol